Metenkefalin/tridecactide

Drug Profile

Metenkefalin/tridecactide

Alternative Names: EK-12; Enkorten

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Farmacija
  • Class Analgesics; Neuropeptides
  • Mechanism of Action Leukocyte stimulants; Opioid delta receptor agonists; Th1 cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Multiple sclerosis
  • Phase III Asthma
  • Phase II Crohn's disease; Ulcerative colitis
  • Phase I Rheumatoid arthritis; Systemic lupus erythematosus
  • Preclinical Psoriasis

Most Recent Events

  • 12 Sep 2017 Bosnalijek plans a phase IIIb trial in Multiple sclerosis (NCT03283397) (Trial profile 700288761)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top